CORPORATE OVERVIEW

For Investor/Corporate Audiences

REGENERON
SCIENCE TO MEDICINE®

Regeneron is a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in four FDA-approved medicines and numerous product candidates in a range of diseases, including rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human genetics sequencing efforts in the world and rapid response technologies being used for global good.

GENERAL COMPANY INFORMATION

– Founded in 1988: Publicly traded company (NASDAQ: REGN) since 1991
– More than 5,000 employees in the U.S. and EU
– Current annualized R&D spending in excess of $1.5 billion; partially supported through research collaborations

LOCATIONS

– Tarrytown, NY: Corporate and Research & Development headquarters
– Rensselaer, NY: Large-scale biologics Industrial Operations and Product Supply (IOPS) facility
– Basking Ridge, NJ: Satellite office
– Dublin, Ireland: EU business office
– Limerick, Ireland: EU IOPS facility (under construction)

LEADERSHIP TEAM

– **Leonard S. Schleifer, MD, PhD**
  Founder, President and Chief Executive Officer
– **George D. Yancopoulos, MD, PhD**
  Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer
  + *Member, National Academy of Sciences*
– **P. Roy Vagelos, MD**
  Chairman of the Board
  + *Former Chief Executive Officer and Chairman of the Board, Merck & Co.*
  + *Member, National Academy of Sciences*
– **Board of Directors** includes two Nobel Laureates and seven members of the National Academy of Sciences

MARKETED PRODUCTS

Praluent®
(alirocumab) Injection 75mg/mL 150mg/mL

– **FDA* approval:** July 2015

EYLEA™
(aflibercept) Injection
For Intravitreal Injection

– **FDA approval for first indication:** November 2011
– **FDA approval for subsequent indications:**
  September 2012, July 2014, October 2014 and March 2015

Arcalyst®
(rilonacept)
Injection for Subcutaneous Use

– **FDA approval:** February 2008

*U.S. Food and Drug Administration.

CLINICAL PRODUCT CANDIDATES

PHASE 1

REGN1979 (CD20/CD3)
Cancer

REGN1979 + REGN2810*
Cancer

REGN1908-1909 (FELD1)
Allergic disease

REGN3470-3471-3479
Ebola

REGN2477 (ACTIVIN A)
Fibrodysplasia ossificans progressiva (FOP)

REGN3500*
Inflammatory diseases

PHASE 2

SARILUMAB*
Noninfectious uveitis

DUPILUMAB*
Atopic dermatitis in children, nasal polyps, eosinophilic esophagitis

TREVOGRUMAB (GDF8)
Skeletal muscle disorders

EVINACUMAB (ANGPTL3)
Homozygous familial hypercholesterolemia, severe forms of hyperlipidemia

RINUCUMAB (PDGFR beta) + AFLIBERCEPT†
Wet age-related macular degeneration

NESVACUMAB (ANG2) + AFLIBERCEPT†
Wet age-related macular degeneration, diabetic macular edema

REGN2810 (PD-1)*
Advanced cutaneous squamous cell carcinoma

*Program partnered with Sanofi.
†Program partnered with Bayer ex-U.S.
‡Program partnered with Teva and Mitsubishi ex-U.S.

This graphic includes pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the disease categories described here.

PHASE 3

ALIROCUMAB*
Cardiovascular outcomes

AFLIBERCEPT†
Diabetic retinopathy without diabetic macular edema

SARILUMAB*
Rheumatoid arthritis

DUPILUMAB*
Atopic dermatitis in adults, asthma

FASINUMAB (NGF)‡
Pain due to osteoarthritis, chronic lower back pain

REGN2222 (RSV)
Respiratory syncytial virus

LEADERS IN TECHNOLOGY

– **Fully human monoclonal antibodies:** Regeneron has developed a suite of patented technologies (VelociSuite®), including VelociGene®, VelocImmune® and VelociMab®, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

– **Fusion proteins:** Our novel and patented "Trap" fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.

– **Regeneron Genetics Center:** A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.

Science: #1 Top Employer, 2016
Forbes: #3 World's Most Innovative Companies, 2016
Fortune: 100 Best Companies to Work For, 2016
*Barron's*: World's Best CEOs, 2016

AWARDS

Scrip Award: R&D Team of the Year, 2016
Crain's New York Business: Fast 50, 2015
Shingo Prize: Operational Excellence, 2013
Scrip Award: Clinical Advance of the Year, 2013

To learn more about us, please visit:

REGENERON.COM
@REGENERON